Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA2 | P00918 | 17/20 | 0.55 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.53 |
| ▸ | CA1 | P00915 | 12/20 | 0.50 |
| ▸ | CA7 | P43166 | 11/20 | 0.50 |
| ▸ | CA12 | O43570 | 9/20 | 0.50 |
| ▸ | CA9 | Q16790 | 9/20 | 0.50 |
| ▸ | CA5A | P35218 | 4/20 | 0.50 |
| ▸ | CA5B | Q9Y2D0 | 4/20 | 0.50 |
| ▸ | CA6 | P23280 | 3/20 | 0.50 |
| ▸ | CA3 | P07451 | 1/20 | 0.50 |
| ▸ | CA14 | Q9ULX7 | 5/20 | 0.49 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.48 |
| ▸ | NR1I2 | O75469 | 1/20 | 0.47 |
| ▸ | TSHR | P16473 | 2/20 | 0.47 |
| ▸ | CA13 | Q8N1Q1 | 2/20 | 0.47 |
| ▸ | CA4 | P22748 | 2/20 | 0.47 |
| ▸ | USP2 | O75604 | 1/20 | 0.46 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.46 |
| ▸ | AGO2 | Q9UKV8 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18713704 | 0.94 | CA2 (0.59) | CA2ALDH1A1CA1CA12CA9 | |
| SCHEMBL20372807 | 0.89 | NR1I2 (0.54) | CA2ALDH1A1CA1CA7CA12 | |
| SCHEMBL15247285 | 0.82 | ALDH1A1 (0.56) | CA2ALDH1A1CA1CA7CA12 | |
| SCHEMBL1626262 | 0.82 | ALDH1A1 (0.56) | CA2ALDH1A1CA1CA7CA12 | |
| SCHEMBL11833604 | 0.82 | CA2 (0.53) | CA2ALDH1A1CA1CA7CA12 | |
| SCHEMBL9450366 | 0.81 | CA2 (0.56) | CA2ALDH1A1CA1CA7CA12 | |
| SCHEMBL20032386 | 0.81 | NR1I2 (0.49) | NR1I2TSHR | |
| SCHEMBL19987486 | 0.81 | PSIP1 (0.52) | ALDH1A1NR1I2 | |
| SCHEMBL13497549 | 0.80 | CA2 (0.52) | CA2ALDH1A1CA1CA7CA12 | |
| Hydrochloric Acid SCHEMBL1185938 | 0.80 | CA2 (0.52) | CA2ALDH1A1CA1CA7CA12 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-119371422-A | Methods for preparing Toll-like receptor modulator compounds | 吉利德科学公司 | 2025-01-28 | — | — | CN | disclosed |
| CN-114269744-B | Methods for preparing Toll-like receptor modulator compounds | 吉利德科学公司 | 2024-10-18 | — | — | CN | disclosed |
| US-11759462-B2 | Spirocyclic compounds as tryptophan hydroxylase inhibitors | ALTAVANT SCIENCES GMBH | 2023-09-19 | — | — | US | disclosed |
| CN-114269744-A | Methods for preparing Toll-like receptor modulator compounds | 吉利德科学公司 | 2022-04-01 | — | — | CN | disclosed |
| US-11155556-B2 | Pyrimido-diazepinone kinase scaffold compounds and methods for treating PI3K-mediated disorders | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2021-10-26 | — | — | US | disclosed |
| US-20210205305-A1 | SPIROCYCLIC COMPOUNDS AS TRYPTOPHAN HYDROXYLASE INHIBITORS | ALTAVANT SCIENCES GMBH (CH) | 2021-07-08 | — | — | US | disclosed |
| US-10946018-B2 | Spirocyclic compounds as tryptophan hydroxylase inhibitors | ROIVANT SCIENCES GMBH (CH) | 2021-03-16 | — | — | US | disclosed |
| US-20200237760-A1 | SPIROCYCLIC COMPOUNDS AS TRYPTOPHAN HYDROXYLASE INHIBITORS | ROIVANT SCIENCES GMBH (CH) | 2020-07-30 | — | — | US | disclosed |
| US-10660893-B2 | Spirocyclic compounds as tryptophan hydroxylase inhibitors | ROIVANT SCIENCES, GmbH (CH) | 2020-05-26 | — | — | US | disclosed |
| US-20190282575-A1 | SPIROCYCLIC COMPOUNDS AS TRYPTOPHAN HYDROXYLASE INHIBITORS | ALTAVANT SCIENCES GMBH (CH) | 2019-09-19 | — | — | US | disclosed |
| CN-110204464-A | A kind of synthetic method of the tertiary sulfamide compound of aryl | 西北师范大学 | 2019-09-06 | — | — | CN | disclosed |
| US-10350208-B2 | Spirocyclic compounds as tryptophan hydroxylase inhibitors | ROIVANT SCIENCES GMBH (CH) | 2019-07-16 | — | — | US | disclosed |
| US-20190106424-A1 | PYRIMIDO-DIAZEPINON KINASE SCAFFOLD COMPOUNDS AND METHODS FOR TREATING P13K-MEDIATED DISORDERS | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2019-04-11 | — | — | US | disclosed |
| US-20180092918-A1 | SPIROCYCLIC COMPOUNDS AS TRYPTOPHAN HYDROXYLASE INHIBITORS | ALTAVANT SCIENCES GMBH (CH) | 2018-04-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10660893-B2 | Spirocyclic compounds as tryptophan hydroxylase inhibitors | TPH1, TPH2, HTR1A | CA2 3523/4885ALDH1A1 433/4885CA1 3748/4885 |
| US-20200237760-A1 | SPIROCYCLIC COMPOUNDS AS TRYPTOPHAN HYDROXYLASE INHIBITORS | TPH1, TPH2, HTR1A | CA2 3523/4885ALDH1A1 433/4885CA1 3748/4885 |
| US-20180092918-A1 | SPIROCYCLIC COMPOUNDS AS TRYPTOPHAN HYDROXYLASE INHIBITORS | TPH1, TPH2, HTR1A | CA2 3523/4885ALDH1A1 433/4885CA1 3748/4885 |
| US-20210205305-A1 | SPIROCYCLIC COMPOUNDS AS TRYPTOPHAN HYDROXYLASE INHIBITORS | TPH1, TPH2, HTR1A | CA2 3523/4885ALDH1A1 433/4885CA1 3748/4885 |
| US-10350208-B2 | Spirocyclic compounds as tryptophan hydroxylase inhibitors | TPH1, TPH2, HTR1A | CA2 3523/4885ALDH1A1 433/4885CA1 3748/4885 |
| US-11155556-B2 | Pyrimido-diazepinone kinase scaffold compounds and methods for treating PI3K-mediated disorders | PI4KA, PIK3CA, PI4KB | CA2 3939/4885ALDH1A1 2810/4885CA1 4677/4885 |
| US-11759462-B2 | Spirocyclic compounds as tryptophan hydroxylase inhibitors | TPH1, TPH2, HTR1A | CA2 3523/4885ALDH1A1 433/4885CA1 3748/4885 |
| US-20190282575-A1 | SPIROCYCLIC COMPOUNDS AS TRYPTOPHAN HYDROXYLASE INHIBITORS | TPH1, TPH2, HTR1A | CA2 3523/4885ALDH1A1 433/4885CA1 3748/4885 |
| US-20190106424-A1 | PYRIMIDO-DIAZEPINON KINASE SCAFFOLD COMPOUNDS AND METHODS FOR TREATING P13K-MEDIATED DISORDERS | PI4KA, PI4KB, PIK3CA | CA2 4116/4885ALDH1A1 3257/4885CA1 4660/4885 |
| US-10946018-B2 | Spirocyclic compounds as tryptophan hydroxylase inhibitors | TPH1, TPH2, HTR1A | CA2 3523/4885ALDH1A1 433/4885CA1 3748/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.